Table 3 Mean change for Q-LES-Q SF percentage maximum scores from baseline to 6 weeks: monotherapy (combined lurasidone treatment groups and placebo)
| Â | Combined treatment dose groups | Placebo | ||||
|---|---|---|---|---|---|---|
| Â | N Mean (SD) | N Mean Change (SD) | P value | N Mean (SD) | N Mean Change (SD) | P value |
Q-LES-Q SF | Â | Â | Â | Â | Â | Â |
Baseline | 317 33.7 (13.4) | -- | Â | 160 34.2 (13.5) | -- | Â |
6-weeks | 244 56.4 (18.7) | 240 22.5 (16.9) | <.0001 | 125 48.7 (20.7) | 124 14.5 (17.0) | <.0001 |